Frankfurt
25.11.25 | 15:29
3,600 Euro
+20,00 % +0,600
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | INVENTIVA: Information relating to the stabilization activities carried out in the context of its recent offering | 240 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), November 24, 2025 - Publication of information relating to the stabilization activities carried out in the context of the recent public offering... ► Artikel lesen | |
| Mo | Inventiva S.A. reports nine-months results | 3 | Seeking Alpha | ||
| Fr | Inventiva S.A reports 9M results | 1 | Seeking Alpha | ||
| Fr | INVENTIVA: Inventiva reports 2025 Third Quarter Financial Information | 683 | GlobeNewswire (Europe) | Cash and cash equivalents at €97.6 million, and €24.7 million in short-term deposits2 as of September 30, 2025.Revenues of €4.5 million for the first nine months of 2025.Cash runway expected until the... ► Artikel lesen | |
| 18.11. | Inventiva stock price target lowered to $11 at Guggenheim on financing | 2 | Investing.com | ||
| INVENTIVA SA ADR Aktie jetzt für 0€ handeln | |||||
| 17.11. | INVENTIVA: Inventiva announces full exercise of Underwriters' Option, bringing proceeds of Offering to approximately $172.5M | 316 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), November 17, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 13.11. | Inventiva S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.11. | Inventiva Prices Of Upsized Public Offering Of About $150 Mln ADS | 1 | RTTNews | ||
| 13.11. | Inventiva resumes trading on Euronext Paris after ADS offering halt | 1 | Investing.com | ||
| 13.11. | Inventiva: Handel an Euronext Paris nach Aussetzung wegen ADS-Angebots wieder aufgenommen | 1 | Investing.com Deutsch | ||
| 13.11. | INVENTIVA: Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares | 296 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), November 13, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 12.11. | INVENTIVA: Inventiva announces launch of public offering | 820 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), November 12, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 06.11. | INVENTIVA: Statement of total voting rights and shares forming the company's share capital as October 20, 2025 | 274 | GlobeNewswire (Europe) | Article R. 22-10-23 of the French Commercial Code Market: Euronext ParisISIN code / Mnemo: FR0013233012 / IVAWeb site: www.inventivapharma.com
Date Number of Shares Outstanding
... ► Artikel lesen | |
| 06.11. | INVENTIVA: Combined General Meeting of November 27, 2025 - Availability of the preparatory documents | 329 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), November 6, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 06.11. | Inventiva S.A. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.10. | Inventiva S.A. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 14.10. | Inventiva S.A. - 6-K, Report of foreign issuer | 19 | SEC Filings | ||
| 14.10. | INVENTIVA: Inventiva Announces the Implementation of a New ATM Program | 479 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), October 14, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 10.10. | Piper Sandler reiterates Overweight rating on Inventiva stock ahead of key trial | 4 | Investing.com | ||
| 10.10. | Piper Sandler bestätigt "Overweight"-Einstufung für Inventiva-Aktie vor wichtiger Phase-3-Studie | 16 | Investing.com Deutsch |
1 2 3 4 Weiter >>
69 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EYEPOINT PHARMACEUTICALS | 12,520 | +0,20 % | EyePoint Pharmaceuticals, Inc.: EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration | - No changes in protocol recommended for LUGANO and LUCIA clinical trials - - Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU - - On track... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 75,25 | +2,35 % | Edwards Lifesciences: Bullischer Impuls am EMA20! | Wo liegen die nächsten Kursziele? Rückblick Edwards Lifesciences ist ein führendes Unternehmen für Innovationen im Bereich der strukturellen Herzerkrankungen. In jüngster Zeit hat Edwards mit soliden... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 1,050 | +1,94 % | Happy Belly Food Group Inc.: Happy Belly Food Group Announces Release Date for Third Quarter Results | Toronto, Ontario--(Newsfile Corp. - November 18, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 154,00 | -1,88 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference | DUBLIN, Nov. 18, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2025 Global Healthcare Conference. Company... ► Artikel lesen | |
| DAIICHI SANKYO | 21,430 | +3,33 % | General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC Platform | - The collaboration will leverage General Proximity's OmniTAC platform to identify and advance next generation induced proximity agents for high value oncology targets. - Induced proximity... ► Artikel lesen | |
| AYTU BIOPHARMA | 1,570 | -100,00 % | Aytu BioPharma, Inc.: Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference | DENVER, CO / ACCESS Newswire / November 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 42,000 | -2,78 % | Rigel Pharmaceuticals auf der Jefferies London Konferenz: Strategisches Wachstum und Pipeline im Fokus | ||
| AUSCANN | - | - | Argent BioPharma Signs $15m Deal to Acquire Key Clinical and IP Assets from AusCann | ||
| TUHURA BIOSCIENCES | 1,640 | 0,00 % | TuHURA Biosciences: Shelf-Registrierung wird wirksam | ||
| NRX PHARMACEUTICALS | 1,980 | +2,06 % | H.C. Wainwright bestätigt Kaufempfehlung für NRx Pharmaceuticals | ||
| CGN MINING | 0,348 | +12,26 % | Dividendenbekanntmachungen (23.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AECON GROUP INC CA00762V1094 0,19 CAD 0,12 EUR ARROWMARK FINANCIAL CORP US8617801043 0,45 USD 0,3905 EUR ASSECO POLAND SA PLSOFTB00016 3... ► Artikel lesen | |
| CHINA SHINEWAY PHARMACEUTICAL GROUP | 0,930 | +2,76 % | Dividendenbekanntmachungen (09.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALUMINUM CORPORATION OF CHINA LTD CNE1000001T8 0,1348 HKD 0,0147 EUR AMEREN CORPORATION US0236081024 0,71 USD 0,6037 EUR ANHUI... ► Artikel lesen | |
| FUTURA MEDICAL | 0,009 | 0,00 % | Futura Medical PLC - PCA Dealing | ||
| BENCHMARK HOLDINGS | 0,256 | -100,00 % | XFRA 31B: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBENCHMARK HLDGS... ► Artikel lesen | |
| BAYER | 30,830 | +0,77 % | Bayer: Einbrüche bei Top-Sellern - und eine große Überraschung | Der DAX-Konzern bekommt zunehmend den generischen Wettbewerbsdruck zu spüren. Beim einstigen Top-Seller Xarelto musste Bayer im dritten Quartal heftige Einbußen hinnehmen. Auf Basis der Q3-Einzelverkäufe... ► Artikel lesen |
INVENTIVA SA ADR gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 3,600 Euro und damit +20,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INVENTIVA SA ADR finden Sie auf Wallstreet Online.